IASLC Full Members receive complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 3% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 23.3, JTO is among the top 3% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews, and opinion pieces. JTO CRR, IASLC’s open-access companion title, publishes a range of manuscripts, from subset analyses of published trials to high-quality case reports. JTO CRR has an Impact Factor of 3.6 and is indexed in PubMed and Web of Science.
JTO by the Numbers
EDITOR-IN-CHIEF, JTO ON 2025 IMPACT FACTOR
Alex A. Adjei, MD, PhD, FACP
"As we celebrate the 20th anniversary of the Journal of Thoracic Oncology (JTO), I want to first thank you all for continuing to make it a trusted and influential publication in the field of thoracic oncology. Our influence as an academic journal is often reflected in the Impact Factor, and your contributions are what help us remain a leader in the field. In 2008, the journal’s impact factor was 3.5. The Impact factor surpassed the 4.0 threshold in 2012 with an impact factor of 4.1.
This year, the JTO Impact Factor is 23.3, up from 20.8 last year, an accomplishment that firmly establishes JTO as a high-impact journal. It currently ranks 3rd among 107 respiratory medicine journals and 15th among 333 oncology journals worldwide.
Beyond its scientific impact, JTO remains committed to helping authors share their research quickly and broadly. With a one-week average to initial decision, fast-track review options, publish-on-acceptance, promotion through social media and press outreach, and the JTO Insights podcast, the journal offers multiple channels to increase the visibility and reach of new research.
The continued prominence of JTO, a single anatomic organ-focused journal in the highly competitive general oncology journal landscape, is due to the support of the IASLC office and IASLC members, committees, as well as our dedicated publishing team and exceptional editorial board members."
JTO CRR By the Numbers
EDITOR-IN-CHIEF, JTO CRR ON 2025 IMPACT FACTOR
Emily Stone, MBBS, PhD, FRACP
"As Editor-in-Chief of JTO Clinical and Research Reports (JTO CRR), the open-access sister journal to JTO, I am pleased to share that we continue to grow in impact and reach, and we are excited to once again report our Impact Factor: 3.6, up from 3.5 last year.
JTO CRR exists to broaden access, increase publishing capacity, and accelerate the dissemination of high-quality thoracic oncology research that complements the flagship JTO.
With this result, JTO CRR ranks 132nd among 333 oncology journals and 31st among 107 respiratory journals. Launching and establishing a new journal in today’s highly competitive publishing landscape is no small undertaking, and this progress reflects the tremendous support of the IASLC, the journal team as a whole, our exceptional Associate Editors, the editorial office staff, and all our reviewers. JTO CRR looks forward to continued growth and an exciting future ahead."
Most-Cited Journal of Thoracic Oncology Articles in 2024
The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11 and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial
Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Small Cell Lung Cancer: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee
The 2021 World Health Organization Classification of Tumors of the Thymus and Mediastinum: What’s new in thymic epithelial, germ cell and mesenchymal tumors?
Recent journal articles
Corrigendum to ‘Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial’ [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistance
ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab
Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement
Clinical Activity of RET Tyrosine Kinase Inhibitor (TKI) plus Chemotherapy after Progression on a RET TKI in a RET Fusion–Positive Non–Small Cell Lung Cancer Real-World Cohort: A Brief Report
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms
Brief Report: The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the 10th Edition TNM Classification
Discover the JTO
JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 1 week to initial decision, and an average of 1.6 weeks for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to JTO@iaslc.org.
Discover the JTO CRR
Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.
In addition to the content discussed previously, JTO CRR also accepts region-specific clinical trials, subspecialty thoracic oncology studies, and select high-quality meeting reports.
To become a JTO CRR Reviewer email your CV to JTOCRR@iaslc.org.
Related Content
